How big is Coherus BioSciences, Inc.?

As of Jun 18, Coherus BioSciences, Inc. has a market capitalization of 87.88 million and reported net sales of 197.49 million with a net profit of -121.77 million over the latest four quarters. As of Dec 24, shareholder's funds were -131.99 million and total assets were 454.85 million.

As of Jun 18, Coherus BioSciences, Inc. has a market capitalization of 87.88 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 197.49 million, while the sum of net profit for the same period is -121.77 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -131.99 million and total assets at 454.85 million.

What does Coherus BioSciences, Inc. do?

Coherus BioSciences, Inc. is a late-stage clinical biologics company focused on developing and commercializing biosimilar products. As of March 2025, it reported net sales of $8 million and a net loss of $47 million, with a market cap of $87.88 million.

Overview: <BR>Coherus BioSciences, Inc. is a late-stage clinical biologics platform company engaged in developing and commercializing biosimilar products within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -47 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 87.88 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: 55.85% <BR>Price to Book: -0.48<BR><BR>Contact Details: <BR>Address: 333 Twin Dolphin Dr Ste 600, REDWOOD CITY CA: 94065-1442 <BR>Tel: 1 650 6493530 <BR>Website: https://www.coherus.com/

Should I buy, sell or hold Coherus BioSciences, Inc.?

Who are in the management team of Coherus BioSciences, Inc.?

As of March 2022, the management team of Coherus BioSciences, Inc. includes Dennis Lanfear (Chairman, President, CEO), Mats Wahlstrom (Lead Independent Director), Alan Mendelson, Mark Stolper, Kimberly Tzoumakas (Directors), and James Healy (Independent Director). They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Coherus BioSciences, Inc. includes the following individuals:<BR><BR>- Mr. Dennis Lanfear, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Mr. Mats Wahlstrom, who is the Lead Independent Director.<BR>- Mr. Alan Mendelson, who is a Director.<BR>- Mr. Mark Stolper, who is also a Director.<BR>- Ms. Kimberly Tzoumakas, who serves as a Director.<BR>- Dr. James Healy, who is an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Coherus BioSciences, Inc. overvalued or undervalued?

Coherus BioSciences, Inc. has a risky valuation grade due to negative metrics like a Price to Book Value of -0.52 and a concerning ROCE of -350.73%, indicating overvaluation despite a recent stock surge, with long-term performance significantly lagging behind the S&P 500.

As of 6 May 2021, the valuation grade for Coherus BioSciences, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative valuation metrics, including a Price to Book Value of -0.52 and an EV to EBITDA of -3.01. Additionally, the company's Return on Capital Employed (ROCE) stands at a concerning -350.73%, further supporting the notion of overvaluation.<BR><BR>In comparison to peers, Coherus BioSciences has a significantly lower EV to EBITDA ratio of 0.2081 compared to SIGA Technologies, Inc., which boasts a ratio of 4.3137 and is rated attractive. Other risky peers like Nurix Therapeutics, Inc. show an EV to EBITDA of -1.2267, but still, Coherus's metrics are alarming. Despite a strong 1-month stock return of 42.99% compared to the S&P 500's 2.33%, the long-term performance is troubling, with a 5-year return of -92.31% versus the S&P 500's 96.61%. This stark contrast highlights the potential risks associated with investing in Coherus BioSciences.

Is Coherus BioSciences, Inc. technically bullish or bearish?

As of September 3, 2025, Coherus BioSciences, Inc. shows a mildly bullish trend with strong short-term performance, having outperformed the S&P 500 recently, but it has underperformed over the longer term.

As of 3 September 2025, the technical trend for Coherus BioSciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. However, the weekly RSI is bearish, and the daily moving averages indicate a mildly bearish stance. Overall, the Dow Theory and KST both reflect a mildly bullish outlook on the weekly and monthly charts. <BR><BR>In terms of performance, Coherus has significantly outperformed the S&P 500 over the past week and month, with returns of 15.04% and 42.99% compared to the S&P 500's 1.05% and 2.33%, respectively. However, over longer periods, such as 3 years and 5 years, the stock has underperformed the benchmark.